Mineralys Therapeutics, Inc. (MLYS)
NMS · Healthcare · Biotechnology
$23.62
-1.34%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$2.08B
Shares Outstanding
88.2M
Exchange
NMS
Currency
USD
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -46.7M | -41.1M | -38.3M | -45.3M |
| Net Income | -43.3M | -36.9M | -32.2M | -39.3M |
| Diluted EPS | $-0.66 | $-0.52 | $-0.40 | $-0.47 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -31.5M | -84.7M | -192.4M | -170.6M |
| Net Income | -29.8M | -71.9M | -177.8M | -154.7M |
| Diluted EPS | $-0.76 | $-1.99 | $-3.66 | $nan |